Hamburg, Germany, 22 January 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

“We are excited to work together with Prof. Sunghoon Kim and our colleagues at Zymedi and Yonsei University to cooperatively advance a particularly promising approach to develop novel antibody-based treatments for asthma and IPF,” said Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec. “The synergies between the three parties supported by the KIAT grant showcase how international collaborations can help accelerate the development of novel therapies for diseases with a high unmet medical need: Dr. Kim’s laboratory at Yonsei University has been recognized as a global leader in the field of tRNA synthetases by uncovering their diverse regulatory activities for body homeostasis. Zymedi is an aspiring Korean company translating the pathologic association of tRNA synthetases to new medicine. Evotec will bring to bear its world-class antibody development, engineering and manufacturing technologies together with its integrated preclinical R&D platforms for drug discovery and development of fibrosis and lung diseases. We are grateful to the Korean government and honored to be part of this outstanding consortium”

“The previously untapped biology of tRNA synthetases provides a versatile route for new drug development. I am very excited to launch the project with Evotec to develop novel therapeutic antibodies targeting a disease-causing activities by these enzymes” said Sunghoon Kim, Professor and Director, Institute of Artificial Intelligence and Biomedical Research at Yonsei University.

The project aims to advance first-in-class antibodies targeting a novel mechanism-of-action in the area of tRNA synthetase biology to treat IPF and non-type 2 asthma. Both disease entities are characterized by a high need to develop novel therapies that will improve future standard-of-care. 

About Yonsei University
Yonsei University, founded in 1885 in Seoul, South Korea, is a prestigious private institution renowned for academic excellence. Ranking #56 in the QS World University Rankings 2025, the university serves approximately 38,725 students across 14 colleges and 15 graduate schools, offering diverse programs in humanities, sciences, engineering, and medicine. Located primarily in Sinchon, Seoul, Yonsei’s mission focuses on educating global leaders committed to humanity’s progress. The university distinguishes itself through extensive research capabilities, 153 research centers, and a strong international perspective. With a rich academic heritage, Yonsei has produced notable alumni including a Nobel laureate and an Academy Award winner. Embodying values of “truth and freedom”, the institution continues to be a leading educational platform preparing students to become innovative global professionals. For additional information please go to www.yonsei.ac.kr.

About Zymedi
Zymedi is a clinical stage biopharmaceutical company pioneering novel biology of aminoacyl-tRNA synthetases (ARSs) as innovative therapeutic solutions. While traditionally known for their role in protein synthesis, ARSs also play crucial roles in the body’s homeostasis—an overlooked function with profound implications for human diseases. Since 2019, Zymedi has focused on harnessing the untapped potential of ARSs, developing first-in-class therapies to address critical unmet medical needs. The company’s proprietary drug discovery platform drives its innovation, enabling a robust pipeline of therapies grounded in deep ARS biology. A current key focus disease area includes immune and fibrotic diseases and cancer. Zymedi is currently collaborating with US National Heart, Lung and Blood Institute for clinical studies of ZMA001, a therapeutic antibody for pulmonary arterial hypertension. The company is located in Incheon, Korea and venture-backed. For additional information, please visit www.zymedi.com and follow us on Instagram @zymedi_official and LinkedIn. 

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

For further information, please contact:

Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com 

Media
Susanne Kreuter 
VP Head of Strategic Marketing 
Susanne.Kreuter@evotec.com  

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE^® Rights ex-US
Sale of GOLIKE^® Rights Outside the U.S. to Nutrisens
Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products

GENEVA (JAN. 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the sale of its intellectual property and commercialization rights for GOLIKE outside the United States to Nutrisens, a leading independent platform that develops and commercializes clinical nutrition solutions for patients. This transaction completes Relief’s previously announced transition from a direct marketing and sales infrastructure to a partnership-based model, enabling the Company to optimize its cost structure and allocate resources on advancing its high-priority R&D programs.

Under the agreement, Nutrisens will take over marketing and sales activities for GOLIKE in Relief’s European markets. Relief has also transferred its existing third-party distribution agreements for GOLIKE in other regions to Nutrisens, while retaining its rights in the United States, where the product is exclusively licensed to Eton Pharmaceuticals. With its significant experience, Nutrisens will continue to support patients and health professionals with GOLIKE solutions worldwide outside the United States. Relief intends to continue to supply GOLIKE globally and complete development of certain line extensions to address patient needs.

“Throughout the past year, we have progressively transformed our organization to build on our strengths in drug development and the business-to-business commercialization of our products,” said Dr. Raghuram Selvaraju, chairman of Relief’s board of directors. “This strategic transformation has refocused our efforts on developing innovative treatments, streamlined operations, and enhanced our ability to serve patients. We are well-positioned to continue advancing our programs in rare dermatology and metabolic disorders, while in parallel, we continue to explore a potential pipeline expansion into the gastrointestinal therapeutic space through our ongoing discussions with Renexxion.”

Relief received CHF 1.2 million upfront from Nutrisens and is eligible for certain contingent payments. Following this payment, Relief reported a cash balance of CHF 15.3 million as of January 22, 2025, ensuring its capacity to achieve key near-term R&D milestones and advance its strategic objectives.

ABOUT GOLIKE^®
GOLIKE products are Foods for Special Medical Purposes (FSMPs) developed by Relief with prolonged-release formulations that closely replicate the physiological absorption of amino acids found in natural proteins. By masking the unpleasant taste and odor typically associated with amino acids, GOLIKE offers a more palatable and patient-friendly solution addressing key challenges in dietary management. The GOLIKE product line includes PKU GOLIKE, designed for the dietary management of phenylketonuria, as well as additional products currently in development.

ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief’s portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Ad hoc announcement pursuant to Art. 53 LR

SKAN announces preliminary key figures for the 2024 financial year

Allschwil, 22 January 2025 – The SKAN Group AG, world market leader for high-quality isolator systems for aseptic production processes in the (bio-) pharmaceutical industry, expects based on preliminary, not yet audited figures net sales of around CHF 360 million (2023: CHF 320.0 million) and earnings before interest, taxes, depreciation and amortization (EBITDA) of around CHF 56 million (2023: CHF 50.1 million). Order intake is expected to reach around CHF 360 million (2023: CHF 295.1 million).

Publication of the 2024 financial results:

SKAN Group AG will publish the detailed 2024 financial results on Tuesday, March 25, 2025, at 7:00 a.m. At the same time, the 2024 Annual Report and the 2024 year-end presentation will be available for download at www.skan.com. An investor, analyst and media conference is also planned for 10:00 a.m. at the Widder Hotel in Zurich. Further details will be provided in due course.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs approximately 1400 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan, the USA and Brazil.

MEDICLIN raises full-year guidance for the 2024 financial year

MEDICLIN Aktiengesellschaft (Ticker: MED) announces that it is raising its guidance for the 2024 financial year.

Instead of a Group EBIT* between EUR 33.0 and 39.0 million, MEDICLIN now expects a Group EBIT between EUR 48.0 and 54.0 million. The sales forecast for the Group was raised from -2.0 % to 0.0 % to now 1.0 % to 3.0 %.

The preliminary figures for the fourth quarter and the 2024 financial year will be published on 27 February 2025.

* As defined on the company’s website at the following link

Contact for further information:
MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg

Ender Gülcan
Head of Investor Relations and Sustainability
Tel.: 0781/488-326
Fax: 0781/488-184
ender.guelcan@mediclin.de
www.mediclin.de
 

Frauenfeld, 21 January 2025

Press release

DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter

• All business divisions contribute to revenue growth in 2024
• OTC revenues increase by 6.7 per cent in 2024
• New Rx customers grew fivefold and Rx revenue up 16.6 per cent in the fourth quarter of 2024
• TeleClinic with profitable doubling of revenue in 2024
• Cash position of CHF 95 million at the end of 2024

DocMorris achieved the communicated revenue target for 2024: External revenue^[1] grew by 6.7 per cent year-on-year in local currency to CHF 1,085.0 million. All business divisions contributed to the sales growth. As at the end of December 2024, the number of active customers[2] increased from 10.2 million in the third quarter of 2024 to 10.3 million. DocMorris successfully completed the break-even programme with the integration of the Zur Rose brand and the closure of the Halle/Saale site.

In the main market of Germany, external revenue in local currency rose by 6.9 per cent to CHF 1,021.9 million in 2024 compared to the previous year. The over-the-counter (OTC) medicines business recorded growth of 6.7 per cent in local currency in 2024 and reached break-even at EBITDA level.

The upward trend in the prescription medicines (Rx) business in Germany accelerated further in the fourth quarter of 2024: After a year-on-year decline of 17.5 per cent in the first quarter of 2024, DocMorris achieved a 16.6 per cent increase in revenue in local currency in the fourth quarter of 2024 compared to the previous year. The number of new Rx customers increased fivefold in the fourth quarter of 2024 compared to the same period of the previous year. New Rx customers have significantly higher order frequencies and basket values than paper Rx customers. Despite significant paper prescription revenue from people with statutory health insurance in the previous year and the delayed introduction of CardLink, the turnaround in prescription redemptions was achieved with revenue growth of 2.1 per cent in local currency in 2024 compared to the previous year. Rx growth continued at over 30 per cent in December until the Christmas week. The first weeks of 2025 show a further acceleration.

Germany’s leading telemedicine platform TeleClinic doubled its revenue to around CHF 11 million in 2024 compared to the previous year with a clearly positive EBITDA contribution. In the Europe segment, which focuses on Spain, France and Portugal, revenue in local currency increased by 3.6 per cent year-on-year to CHF 63.1 million in 2024.

DocMorris has cash and cash equivalents of CHF 95 million at the end of 2024.

Outlook confirmed
DocMorris confirms the targets for 2024 communicated in August:

• Adjusted EBITDA of around minus CHF 50 million, including e-prescriptions
• Capital expenditure of around CHF 30 million

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. In 2024, around 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

^[1] External revenue consists of the consolidated revenue of DocMorris plus online revenues of pharmacies supplied by DocMorris, less the consolidated revenue from supplying them.

^[2] Customers supplied by DocMorris, either directly or through its partners

Marinomed Biotech AG: Restructuring proceedings successfully completed

• Restructuring proceedings formally ended by resolution of the Korneuburg regional court after meeting all necessary conditions, including unanimous approval of the restructuring plan
• Management Board takes over administration of Company from insolvency administrator
• Restructuring plan to be fulfilled within the next two years; necessary funds to be obtained from sale of Carragelose business and commercialization of Marinosolv asset

Korneuburg, Austria, 20. January 2025 – Marinomed Biotech AG (VSE:MARI) announces that the restructuring proceedings without self-administration opened on August 14^th, 2024, have been formally completed by resolution of the Korneuburg regional court on January 14^th, 2025. In December, the Company met all necessary prerequisites, including depositing the funds required for payment of the cash quota and the costs of the proceedings. With the formal end of the proceedings, administration by the insolvency administrator has also ended and the Management Board has regained control over the Company.

Prior to this, unanimous approval of the restructuring plan was obtained from the creditors, in particular the European Investment Bank. The plan provides for a quota of 30%, payable within the next two years. Key element of fulfilling the plan is the sale of the Carragelose business to Unither Pharmaceuticals. Shareholders’ approval, which is one major closing condition for this deal, has been obtained in an extraordinary general meeting on December 19^th, 2024.

“We are relieved that we were able to successfully complete the restructuring process. With the sale of the Carragelose business, we are well positioned to fulfill the restructuring plan. At the same time, our top priorities are now to develop a new strategy and to push ahead with the commercialization of our Marinosolv and Solv4U assets”, Andreas Grassauer, CEO of Marinomed, adds.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

Press Release // January 20, 2025

Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea^®, under the brand names AHZANTIVE^® and Baiama^®

• FYB203 (aflibercept) approved for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
• AHZANTIVE^® and Baiama^® offer patients treated with Eylea^® a new high-quality therapeutic option
• Teva Pharmaceuticals will semi-exclusively market FYB203 under the brand name AHZANTIVE^® in major parts of Europe

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH (“Klinge”) today jointly announce that the European Commission has granted central marketing authorization for FYB203 (Aflibercept), a biosimilar to Eylea^®1, under the brand names AHZANTIVE^®2 and Baiama^®3. The approval encompasses the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal Neovascularisation (CNV) and Macular Edema following Retinal Vein Occlusion (RVO). The decision of the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) from November 2024 and applies to all countries in the European Economic Area (EEA), including the 27 member states of the European Union (EU) as well as Iceland, Liechtenstein, and Norway.

Dr. Stefan Glombitza, CEO of Formycon AG, commented: “The EU approval of FYB203, our biosimilar for Eylea^®, marks another milestone for Formycon and is based on the expertise and dedication of our entire team. As our second ophthalmic biosimilar, FYB203 significantly expands therapeutic options for patients with severe retinal diseases. With AHZANTIVE^® and Baiama^®, we are improving access to high-quality and affordable therapies that contribute sustainably to enhancing patients’ quality of life.”

Aflibercept inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina, thereby impairing vision. In 2023, the reference product Eylea^® achieved global sales of approximately USD 9 billion⁴, highlighting the significance and necessity of a cost-effective alternative like FYB203.

In mid-January 2025, Formycon and Teva Pharmaceuticals International GmbH (Teva) signed a licensing agreement for the semi-exclusive commercialization of FYB203 across major parts of Europe and Israel. Concurrently, Formycon has concluded an agreement with Teva for product supply. FYB203 was already approved by the U.S. Food and Drug Administration (FDA) in June 2024.

————————————————————————————-

¹⁾ Eylea^® is a registered trademark of Regeneron Pharmaceuticals Inc.
²⁾ AHZANTIVE^® is a registered trademark of Klinge Biopharma GmbH
³⁾ Baiama^® is a registered trademark of Klinge Biopharma GmbH
⁴⁾ Source: https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2023-financial/

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe, the USA, and the MENA-region. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, received FDA and European Commission approval; FYB202 is also approved in the UK and Canada. Another four biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG, headquartered in Munich, is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX and TecDAX selection indices. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Mail: Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures 2024: Net sales just below and earnings just above expectations –Forecast 2025

Lübeck, January 15, 2025 – Based on preliminary calculations, Dräger’s net sales in fiscal year 2024 increased by 0.6 percent (net of currency effects; nominal: 0.0 percent). Net sales were thus just below the last forecast, according to which Dräger had expected an increase in net sales in the range of 1.0 to 3.0 percent (net of currency effects). At around EUR 3,373 million, net sales nevertheless came close to the high figure of the prior year (2023: EUR 3,373.5 million), in which Dräger had benefited from strong catch-up effects as a result of the noticeable improvement in delivery capability and the surge in demand for ventilators in China. As expected, these two effects were absent in 2024.

The safety division continued its growth in the 2024 fiscal year and recorded an increase in net sales of 5.1 percent (net of currency effects; nominal: 4.7 percent) to around EUR 1,473 million (2023: EUR 1,407.3 million). The medical division saw a decline of 2.6 percent (net of currency effects; nominal: -3.4 percent) to around EUR 1,900 million (2023: EUR 1,966.2 million), which is attributable in particular to the aforementioned base effects in the prior year and the current difficult market conditions in China. The Group’s gross margin rose to around 45.0 percent (2023: 43.3 percent).

Earnings before interest and taxes (EBIT) increased significantly by around 19 percent to around EUR 197 million (2023: EUR 166.4 million). In addition to the operating business performance, several one-time effects with an impact on earnings amounting to around EUR 22 million had a positive effect on EBIT. At 5.8 percent (2023: 4.9 percent), the EBIT margin was just above the last annual forecast (range of 4.0 to 5.5 percent).

At around EUR 3,381 million, Dräger’s order intake was up 3.4 percent (net of currency effects; nominal: 2.7 percent) on the high prior-year figure (2023: EUR 3,290.0 million). Both divisions contributed to this positive development: order intake in safety rose by 6.5 percent (net of currency effects; nominal: 6.1 percent) to around EUR 1,457 million (2023: EUR 1,373.8 million), while order intake in medical increased by 1.2 percent (net of currency effects; nominal: 0.4 percent) to around EUR 1,923 million (2023: EUR 1,916.2 million) following a decline in the prior year.

Dividend proposal
In line with the existing dividend policy, Dräger intends to distribute around 30 percent of the group net profit to its shareholders. The final dividend proposal will be made with the final business figures for 2024.

Forecast for 2025
For the current fiscal year, Dräger expects an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent. The expected EBIT margin is therefore in line with our goal of increasing the EBIT margin by an average of one percentage point each year.

The full 2024 Annual Report will be published on April 3, 2025.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects

• Group cash and cash equivalents improved to € 27.2 million
• Successfully closed two milestone transactions with Royalty Pharma and Akribion Therapeutics
• Management sees a strong start to the new financial year
• Updated mid-term targets at the CMD 2024 and well-founded optimism for new business year 2024/25

ZWINGENBERG, Germany, January 15, 2025 – BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biosolutions for industry, has published the BRAIN Biotech Group´s financial figures for the fiscal year 2023/24. The Group’s cash position has been built up during the year to a strong € 27.2 million.

The company successfully closed two milestone transactions in the last financial year: first, a royalty monetization with Royalty Pharma with potential proceeds from milestone payments of up to € 128.88 million; second, an exclusive pharma licensing deal with Akribion Therapeutics for up to € 92.3 million in milestones plus royalties on net sales. Consolidated revenue in the 2023/24 financial year was roughly flat at € 54.6 million.

CEO Adriaan Moelker says: “With two closed benchmark transactions from our BioIncubator pipeline we were able to develop the Group significantly from a strategic perspective while our revenue growth has taken a breather during the last financial year. I am very confident about the growth prospects for the current year and our mid-term target to reach € 100 million revenues in the BRAINBiocatalysts segment within the next five years. We have a good and solid foundation on which to build, our markets are large and attractive, and we have the tools to succeed.”

BRAIN Biotech reported an adjusted EBITDA of € – 0.4 million compared to € +0.4 million last year despite macroeconomic headwinds and high investments in the Group’s BioIncubator projects. CFO Michael Schneiders states: “During a year full of economic challenges we have managed to keep our adjusted EBITDA close to breakeven. With a strong focus on the successful execution of strategic initiatives we have been able to bring our group cash position to a very comfortable level of € 27.2 million and to reduce our cost base significantly for the running financial year. We have laid excellent foundations for success in the years to come. Hence, we forecast a clearly positive adjusted EBITDA for 2024/25.”

Development of the segments

In the reporting period, BRAIN Biotech’s business activities were structured into the operating segments BioProducts, BioScience and BioIncubator.

The BioProducts segment mainly consists of its industrially scalable products business focusing on specialized enzymes and proteins. Revenue development in this segment was nearly flat at € 42.6 million versus € 42.5 million in the previous financial year. While some sub-segments have been growing very dynamically other business activities within the segment performed below expectations. This was particularly due to the slower than expected ramp curve of the second large-scale fermenter. The fermenter has now been successfully commissioned. The segment’s total operating performance retracted slightly from € 42.8 million in the previous year to € 42.6 million. The segment’s adjusted EBITDA was at € 5.3 million versus € 5.5 million last financial year. This slight decline is mainly attributable to adverse product mix changes and the costs associated with the ramp of the second large scale fermenter.

The BioScience segment includes the research and development business with industrial partners. In this segment, revenue decreased by 13.1 % from € 12.3 million to € 10.7 million. This is attributable to the generally weak economic environment and corresponding postponements in the project business. Total operating performance decreased by € 2.2 million to € 11.2 million. The segment’s adjusted EBITDA stood at – € 0.2 million after € 0.8 million in the previous financial year.

The BioIncubator segment includes the external R&D project pipeline and the company’s own R&D projects offering high value-creation potential. The segment generated revenue of € 1.7 million, which was strongly up from € 0.6 million in the previous reporting period. This revenue was generated primarily by milestone and license income from pharma-related projects. The segment’s negative adjusted EBITDA is mainly driven by high investments in genome editing and amounted to € -2.1 million in the financial year (previous € -2.7 million). Gross investments into the Akribion Genomics platform were € 3.0 million versus € 3.3 million in the previous year.

Key financials from Financial Year 2023/24:

1 Revenues + change in inventories + other income including R&D grants

2 The reconciliation from adjusted to unadjusted EBITDA can be found in the Annual report 2023/24

Outlook for 2025

For the financial year 2024/25 BRAIN Biotech expects to accelerate its revenue growth path in-line with the projected mid-term growth forecast. Adjusted EBITDA growth is expected to be above sales growth. In line with its communicated strategy the company will continue to explore bolt-on acquisitions that can add product expertise and accelerate growth further.

The full quantitative guidance for the financial year 2024/25 will be issued with the 3M reporting on February 26, 2025.

The company had recently updated its mid-term guidance during the 2024 Capital Markets Day. BRAIN Biotech will further sharpen its focus on profitable growth and now targets for its growth segment BRAINBiocatalysts € 100 million revenues and an adjusted EBITDA margin of 15 % within the next five years. In addition, the company intends to continuously harvest high value opportunities from its BioIncubator pipeline.
 

Link to BRAIN Biotech AG Annual Report 2023/24:

https://reports.brain-biotech-group.com/report-2024/en/

+++

BRAIN Biotech Group

The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio.

The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA.

BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 325 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com.

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

The BRAIN Biotech Group on social media and on the internet:

BRAIN Biotech Group

Web: www.brain-biotech-group.com

LinkedIn: https://www.linkedin.com/company/brainbiotech

Threads: https://www.threads.net/@brainbiotechag

Bluesky: https://bsky.app/profile/brain-biotech-group.com

X: https://x.com/BRAINbiotech

Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg

Biocatalysts Ltd (Production, Sales)

LinkedIn:

Biocatalysts Ltd on LinkedIn

Biocatalysts Baking on LinkedIn

BRAIN-Biocatalysts Life Science Solutions on LinkedIn

BRAIN Biotech Zwingenberg (Research & Development)

Web: www.brain-biotech.com

AnalyticonDiscovery (Research & Development)

Web: https://ac-discovery.com/

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.
 

Legalization of cannabis brings strong growth: Cantourage Group SE increases its sales by 118% to EUR 51.4 million in full year 2024

Berlin, January 15, 2025 – Cantourage Group SE (hereafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe’s leading publicly listed cannabis company, posted sales of EUR 51.4 million in the full year 2024. This exceeded the most recently raised sales forecast for 2024 (EUR 46 million to EUR 50 million). The growth in sales in 2024 represents an increase of 118% compared to the previous year (2023: EUR 23.6 million) and demonstrates the exceptional scalability and performance of Cantourage’s business model.

On a monthly and quarterly basis, Cantourage continued to see strong growth in sales throughout 2024. At the end of the year, Cantourage once again set new sales records at both the monthly and quarterly level:

• Sales in December 2024: EUR 8.5 million (previous record: EUR 7.2 million; November 2024)
• Sales in Q4 2024: EUR 21.2 million (previous record: EUR 13.2 million; Q3 2024)

The main driver of this positive business performance was the continuously growing demand for Cantourage’s cannabis flowers, especially in Germany and the UK. By significantly expanding its own processing capacities, the company was increasingly able to meet the sustained increase in demand for cannabis-based pharmaceuticals in its various markets over the course of 2024.

“2024 was a very eventful year for cannabis in Germany. Over the course of the year, it became clear that the partial legalization in April is giving more and more people access to medical cannabis – and bringing enormous economic potential for the entire industry. We are pleased to be able to meet the growing demand for high-quality, safe cannabis flowers together with our strong partner network. Despite all the macroeconomic challenges, we have now exceeded the EUR 50 million sales mark only five and a half years after our company was founded. We have thus increased our sales revenues of around EUR 500,000 in 2020, when we launched our first product, by more than a hundredfold,” said Philip Schetter, CEO of Cantourage.

“For 2025, we have already launched new growth drivers such as our recent very successful market entry in Poland or the relaunch of our telemedicine platform www.telecan.de,” emphasizes Philip Schetter. “By doing so, we want to support even more people on their way to cannabis therapy and expand our leading position in the dynamic European market environment – while continuing to grow profitably as a company. With the help of our asset-light business model, we will be able to realize this growth using our own resources. Overall, we will place a strong emphasis on continuously improving our efficiency, making even better use of economies of scale and significantly increasing our profitability even further.”
 

About Cantourage

Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.”

Further information: www.cantourage.com
 

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
 

Press contact at Cantourage:

Frederick Steudemann
Tel. +49 (0)30 4701 350 – 50
steudemann@cantourage.com